What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
CIK: 0001846444
Total reported value
$613.5M
$613.5M
21 檔
55.4%
During the Q4 2024 filing period, Sands Capital Alternatives, LLC (CIK: 0001846444) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $613.5M across 21 reported positions.
During Q4 2024, Sands Capital Alternatives, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KVYO | Klaviyo Inc-a | Stock-Other | 31.13% | -7.19% | -1.27% | |
| 2 | NU | Nu Holdings Ltd. | Stock-Financials | 15.82% | -6.85% | +27.69% | |
| 3 | DASH | Doordash Inc - A | Stock-Consumer Disc | 14.86% | -0.13% | -3.78% | |
| 4 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 7.74% | -0.88% | — | |
| 5 | CPNG | Coupang Inc | Stock-Consumer Disc | 4.42% | -0.78% | +7650.50% | |
| 6 | PATH | Uipath Inc - Class A | Stock-Tech | 4.38% | — | +37.17% | |
| 7 | DDOG | Datadog Inc - Class A | Stock-Tech | 3.04% | +1.03% | +6855.05% | |
| 8 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 2.78% | -0.04% | — | |
| 9 | MNDY | monday.com Ltd. | Stock-Tech | 2.47% | -0.14% | — | |
| 10 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 2.05% | -0.55% | — | |
| 11 | IOT | Samsara Inc-cl A | Stock-Tech | 1.89% | -1.49% | +6163.87% | |
| 12 | TOST | Toast Inc-class A | Stock-Tech | 1.84% | -0.25% | +5099.42% | |
| 13 | TXG | 10x Genomics Inc-class A | Stock-Other | 1.50% | +0.58% | — | |
| 14 | SNOW | Snowflake Inc | Stock-Tech | 1.31% | +0.29% | -63.98% | |
| 15 | ABOS | Acumen Pharmaceuticals Inc | Stock-Other | 1.28% | -0.46% | — | |
| 16 | CRWD | Crowdstrike Holdings Inc - A | Stock-Tech | 1.27% | — | +7637.56% | |
| 17 | BIOA | Bioage Labs Inc | Stock-Other | 0.99% | -0.13% | -27.62% | |
| 18 | CADL | Candel Therapeutics Inc | Stock-Other | 0.77% | +0.21% | — | |
| 19 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.27% | +0.03% | — | |
| 20 | MASS | 908 Devices Inc | Stock-Other | 0.11% | — | — | |
| 21 | SPRU | Spruce Power Holding Corporation | Stock-Other | 0.07% | — | -9.05% |
According to official SEC Form 13F filings, Sands Capital Alternatives, LLC reported a total U.S. public equity portfolio value of $613.5M across 21 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including KVYO, NU, DASH) accounted for 55.4% of total reported equity market value during Q4 2024.
During Q4 2024, Sands Capital Alternatives, LLC's top holdings by market value included KVYO (31.1%)、NU (15.8%)、DASH (14.9%). The largest single position, KVYO, represented 31.1% of total portfolio value.
In Q4 2024, Sands Capital Alternatives, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.